Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legacy Of Many Sponsors Complicated Review Of Vanda's Fanapt

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The multiple sponsors of the antipsychotic Fanapt (iloperidone) produced an inconsistent development program followed by a tumultuous and ultimately dramatic review as FDA worked through a succession of issues surrounding clinical trial design and analysis choices.

You may also be interested in...



Fanapt Pharmacogenetic Data Suggestive But Not Conclusive, FDA Finds

FDA's review of the pharmacogenetic data in Vanda's NDA for Fanapt (iloperidone) suggests that sponsors should be prepared for the agency to require significant clinical evaluation before including pharmacogenetic criteria in labeling

Fanapt Pharmacogenetic Data Suggestive But Not Conclusive, FDA Finds

FDA's review of the pharmacogenetic data in Vanda's NDA for Fanapt (iloperidone) suggests that sponsors should be prepared for the agency to require significant clinical evaluation before including pharmacogenetic criteria in labeling

FDA's U-Turn On Fanapt: Comparative Assessments Must Have Clinical Meaning

The review of Vanda’s Fanapt casts into relief the contours of FDA’s authority to consider comparative efficacy as a factor in drug approval decisions.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel